MedTrace Logo

ImproveR International (BI-001-IM)

NCT00290849 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2012-05-07

No results posted yet for this study

Summary

The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting. In particular, data will be collected to analyze experiences of bivalirudin use in respect to the following objectives;

* examine the aspects of safety and effectiveness of bivalirudin
* gain experience regarding the characteristics of patients in bivalirudin treatment
* evaluate the handling of bivalirudin and its practicality

Conditions

  • Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)

Interventions

DRUG

Bivalirudin

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Nycomed Clinical Trial Operations · Headquaters

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-06-30
Completion
2007-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290849 on ClinicalTrials.gov